<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03580408</url>
  </required_header>
  <id_info>
    <org_study_id>NIVINIHO</org_study_id>
    <nct_id>NCT03580408</nct_id>
  </id_info>
  <brief_title>Study Of Nivolumab Alone, Or In Combination With Vinblastin In Patients With Classical Hodgkin Lymphoma</brief_title>
  <official_title>A Prospective Phase II Study Of Nivolumab Alone, Or In Combination With Vinblastin In Patients Aged 61 Years And Older, With Classical Hodgkin Lymphoma And Coexisting Medical Conditions.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Lymphoma Academic Research Organisation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Lymphoma Academic Research Organisation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multicentric phase II open-label trial consisting of 6 cycles Nivolumab (2&#xD;
      weeks interval) followed by a PET-CT scan. The treatment will be allocated according to PET&#xD;
      and CT scan responses. :&#xD;
&#xD;
        -  In case of CMR according to Lugano Classification (Cheson et al.2014, PET-CT based&#xD;
           response), patients will receive 18 additional cycles of Nivolumab, according to&#xD;
           CT-based response at Cycle 12.&#xD;
&#xD;
        -  In case of Partial Metabolic Response (PMR) or No Metabolic Response(NMR), according to&#xD;
           Lugano Classification (Cheson et al.2014, PET-CT based response) patients will receive&#xD;
           12 to 18 cycles of Nivolumab combined with Vinblastin according to CT-based response at&#xD;
           Cycle 12.&#xD;
&#xD;
        -  In case of progressive disease, according to Lugano Classification (Cheson et al.2014,&#xD;
           PET-CT scan based response) patients will be considered in treatment failure.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 31, 2018</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Actual">February 19, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete Metabolic Response (CMR) rate (Deauville scale 1-3) at the end of treatment</measure>
    <time_frame>12 months</time_frame>
    <description>by the Lugano classification 2014</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quantity of drug taken</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Serious Adverse Event</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival (EFS)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Metabolic Response (CMR) rate</measure>
    <time_frame>3 months</time_frame>
    <description>by the Lugano classification 2014 at the end of induction treatment</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Hodgkin Lymphoma</condition>
  <condition>Coexisting Medical Conditions</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction treatment :Nivolumab will be given alone at 240 mg flat dose every 2 weeks (i.e. one cycle) Patients will be assessed after 3 months of therapy (after 6 injections of Nivolumab)&#xD;
Consolidation treatment:&#xD;
It depends on the induction evaluation by PET-CT and CT-scan (Lugano 2014 criteria) :&#xD;
For patients achieving CMR according to Lugano Classification : treatment by nivolumab 240 mg every 2 weeks for 9 months.&#xD;
Patients who reach PMR and NMR after 3 months (according to Lugano Classification) will be treated by the Nivolumab+Vinblastin regimen every 2 weeks for 9 additional months: Vinblastin(6 mg/m2 (IV) + Nivolumab 240 mg (IV)&#xD;
In case of progressive disease , patients will be considered in treatment failure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>240 mg</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinblastin</intervention_name>
    <description>6mg/m²</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  first diagnosis of classical Hodgkin lymphoma according to World Health Organization&#xD;
             (WHO) criteria excluding nodular lymphocyte predominant subtype&#xD;
&#xD;
          -  Age 61 years or older&#xD;
&#xD;
          -  Unfit for poly chemotherapy because of co-morbidities evaluated by a Cumulative&#xD;
             Illness Rating Scale (CIRS) score ≥6)&#xD;
&#xD;
          -  No previous treatment for Hodgkin lymphoma&#xD;
&#xD;
          -  Ann Arbor stages: I-IV&#xD;
&#xD;
          -  Baseline 18-fluoro-2-deoxy-D-glucose (18F-FDG) PET-CT (PET0) performed before any&#xD;
             treatment with at least one hypermetabolic lesion&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-3&#xD;
&#xD;
          -  minimum life expectancy of 3 months&#xD;
&#xD;
          -  covered by a social security system&#xD;
&#xD;
          -  Men who are sexually active with women with childbearing potential must agree to&#xD;
             follow instructions for method(s) of contraception for the duration of treatment with&#xD;
             study drug and for at least 7 months after the last drug administration.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contra-indication to Nivolumab and /or Vinblastin&#xD;
&#xD;
          -  Subjects with active interstitial pneumonitis&#xD;
&#xD;
          -  Subjects with active infectious disease&#xD;
&#xD;
          -  Subjects with active, known or suspected autoimmune disease. Are permitted to enroll:&#xD;
             subjects with vitiligo, type I diabetes mellitus, residual hypothyroidism due to&#xD;
             autoimmune condition only requiring hormone replacement, psoriasis not requiring&#xD;
             systemic treatment, or conditions not expected to recur in the absence of an external&#xD;
             trigger.&#xD;
&#xD;
          -  Any serious active disease, severe cardio-pulmonary, or metabolic disease interfering&#xD;
             with normal application of protocol treatment (according to the investigator's&#xD;
             decision)&#xD;
&#xD;
          -  Any of the following abnormal laboratory values (unless due to underlying HL) :&#xD;
&#xD;
               1. Calculated creatinine clearance &lt; 30 mL/min (MDRD formula)&#xD;
&#xD;
               2. aspartate transaminase (AST) or alanine transaminase (ALT) &gt; 2.5 times the upper&#xD;
                  limit of normal (ULN)&#xD;
&#xD;
               3. Serum total bilirubin &gt; 30µmol/L&#xD;
&#xD;
               4. Neutrophils&lt;1 G/L or Platelets&lt;50 G/L, (unless related to bone infiltration by&#xD;
                  lymphoma)&#xD;
&#xD;
          -  Any history of cancer evolution requiring therapy during the last 3 years with the&#xD;
             exception of non-melanoma skin tumors or stage 0 (in situ) cervical carcinoma.&#xD;
             Patients previously diagnosed with prostate cancer are eligible if :&#xD;
&#xD;
               1. Their disease was T1-T2a, N0, M0, with a Gleason score ≤ 7, and a prostate&#xD;
                  specific antigen (PSA) ≤ 10 ng/mL prior to initial therapy,&#xD;
&#xD;
               2. They had definitive curative therapy (ie, prostatectomy or radiotherapy) ≥ 2&#xD;
                  years before Day 1 of Cycle 1,&#xD;
&#xD;
               3. At a minimum 2 years following therapy they had no clinical evidence of prostate&#xD;
                  cancer, and their PSA was undetectable if they underwent prostatectomy or &lt;1&#xD;
                  ng/mL if they did not undergo prostatectomy.&#xD;
&#xD;
          -  Uncontrolled diabetes mellitus leading to impossibility to perform PET scan&#xD;
&#xD;
          -  Treatment with any investigational drug within 30 days before planned first cycle of&#xD;
             chemotherapy and during the study&#xD;
&#xD;
          -  Adult person under legal protection&#xD;
&#xD;
          -  Adult person unable to provide informed consent because of intellectual impairment,&#xD;
             any serious medical condition, laboratory abnormality or psychiatric illness&#xD;
&#xD;
          -  Subjects with know Human Immunodeficiency Virus (HIV) positivity&#xD;
&#xD;
          -  Subjects with known active hepatitis B (HB) infection (positive Ag HB s or positive&#xD;
             DNA polymerase chain reaction (PCR) or positive antibody anti-HB c with lack of&#xD;
             antibody against HBs) or active hepatitis C infection (patients with positive HCV&#xD;
             serology are eligible only if PCR is negative for known hepatitis C virus (HCV RNA)&#xD;
&#xD;
          -  Subjects with a condition requiring systemic treatment with either corticosteroids (&gt;&#xD;
             10mg daily prednisone equivalents) or other immunosuppressive medications within 14&#xD;
             days of study drug administration except for adrenal replacement steroid doses &gt; 10 mg&#xD;
             daily prednisone equivalent in the absence of active autoimmune disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>61 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vincent RIBRAG</last_name>
    <role>Study Chair</role>
    <affiliation>Institut Gustave Roussy Cancer, Villejuif, France - LYSA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Julien LAZAROVICI</last_name>
    <role>Study Chair</role>
    <affiliation>Institut Gustave Roussy Cancer, Villejuif, France - LYSA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marc ANDRE</last_name>
    <role>Study Chair</role>
    <affiliation>CHU Dinant Godinne, UCL Namur, Yvoir - Belgium - LYSA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ZNA Stuivenberg</name>
      <address>
        <city>Antwerpen</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Az Sint Jan</name>
      <address>
        <city>Bruges</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Universitaire Saint LUC</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Jolimont</name>
      <address>
        <city>Haine saint paul</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Az Groeninge</name>
      <address>
        <city>Kortrijk</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Liege</name>
      <address>
        <city>Liege</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Dinant Godinne</name>
      <address>
        <city>Yvoir</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU UCL Namur</name>
      <address>
        <city>Yvoir</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU d'Amiens</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH d'Avignon - Hôpital Henri Duffaut</name>
      <address>
        <city>Avignon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Côte Basque</name>
      <address>
        <city>Bayonne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Besançon - Hôpital Jean Minjoz</name>
      <address>
        <city>Besançon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonié - Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut d'Hématologie de Basse Normandie - CHU Côte de Nacre</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Métropole Savoie</name>
      <address>
        <city>Chambery</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Clermont Ferrand</name>
      <address>
        <city>Clermont Ferrand</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Sud Francilien de Corbeil</name>
      <address>
        <city>Corbeil Essonnes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>APHP-Hôpital Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Dijon - Hôpital le Bocage</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHD de Vendée</name>
      <address>
        <city>La Roche-sur-Yon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH La Rochelle</name>
      <address>
        <city>La Rochelle</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH du Mans</name>
      <address>
        <city>Le Mans</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Saint Vincent de Paul</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de LILLE - Claude Huriez</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Limoges</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon Cedex 8</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmette</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Metz-Thionville</name>
      <address>
        <city>Metz</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Montpellier - Saint Eloi</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes - Hôtel Dieu</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nîmes - Caremeau</name>
      <address>
        <city>Nimes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>APHP - Hôpital Saint Louis</name>
      <address>
        <city>Paris Cedex 10</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>APHP - Hopital Necker</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>APHP - Hôpital de la Pitié Salpetrière</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre François Magendie - Hôpital du Haut Lévêque</name>
      <address>
        <city>Pessac</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Lyon Sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Poitiers - Hôpital de La Milétrie</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ch Rene Dubos</name>
      <address>
        <city>Pontoise</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Annecy-Genevois - Site d'Annecy</name>
      <address>
        <city>Pringy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Robert Debré</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes - Hôpital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de Roubaix</name>
      <address>
        <city>Roubaix</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de Saint Brieuc</name>
      <address>
        <city>Saint-Brieuc</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IUCT Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Bretonneau</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Brabois</name>
      <address>
        <city>Vandoeuvre les Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>VILLEJUIF Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 26, 2018</study_first_submitted>
  <study_first_submitted_qc>June 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 9, 2018</study_first_posted>
  <last_update_submitted>July 23, 2021</last_update_submitted>
  <last_update_submitted_qc>July 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nivolumab</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>Anti-PD1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

